Page last updated: 2024-12-11
ketoprofen lysine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
ketoprofen lysine: lysine salt of ketoprofen; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 9843941 |
CHEMBL ID | 4650345 |
SCHEMBL ID | 4623586 |
MeSH ID | M0095125 |
Synonyms (26)
Synonym |
---|
ketoprofen lysine |
lysyl-ketoprofen |
l-lysine, mono(3-benzoyl-alpha-methylbenzeneacetate) |
ketoprofen lysine salt |
artrosilene (tn) |
57469-78-0 |
D08102 |
artrosilene |
ketoprofen lysinate |
5wd00e3d4c , |
unii-5wd00e3d4c |
ketoprofen lysine salt [mi] |
ketoprofen l-lysinate |
ketoprofen lysine [who-dd] |
l-lysine, 3-benzoyl-.alpha.-methylbenzeneacetate (1:1) |
AKOS025311486 |
SCHEMBL4623586 |
mfcd03701078 |
(s)-2,6-diaminohexanoic acid compound with 2-(3-benzoylphenyl)propanoic acid (1:1) |
AS-17318 |
Q27262959 |
2-(3-benzoylphenyl)propanoic acid;(2s)-2,6-diaminohexanoic acid |
CHEMBL4650345 |
CS-0137969 |
ketoprofen (lysinate) |
HY-B0227A |
Research Excerpts
Effects
Ketoprofen lysine salt (KLS) has a potent anti-inflammatory activity associated with effective analgesic and antipyretic effects. KLS has a neutral pH and does not irritate the gastrointestinal tract, that determines the safety of its used.
Treatment
Excerpt | Reference | Relevance |
---|---|---|
"Treatment with ketoprofen lysine salt demonstrated a significantly more marked (p < 0.001) anti-inflammatory effect than placebo as regards all variables considered: burning, sensation pain, oedema and erythema, and by the 3rd day of treatment led to significant remission of the symptomatology. " | ( [The efficacy of and tolerance for ketoprofen lysine salt in solution for oropharyngeal use in inflammatory lesions of the oral cavity]. de' Lorenzi, C; Natale, F, 1997) | 0.93 |
Toxicity
Excerpt | Reference | Relevance |
---|---|---|
" Adverse drug-related effects reported included numbness of the tissues in the oral cavity, sensation of tingling in the tissues in the oral cavity, dry mouth, thirst, and nausea." | ( Efficacy and safety of ketoprofen lysine salt mouthwash versus benzydamine hydrochloride mouthwash in acute pharyngeal inflammation: a randomized, single-blind study. Bellussi, L; Damiani, V; Passàli, D; Passàli, GC; Volonté, M, 2001) | 0.62 |
Bioavailability
Excerpt | Reference | Relevance |
---|---|---|
" The slow-release preparation had a bioavailability greater than 90% as compared with the conventional capsule and produced lower and longer lasting ketoprofen serum levels." | ( Pharmacokinetics of a slow-release preparation of ketoprofen lysine in man. Borsa, M; Canali, S; Ronchi, C; Tonon, GC; Zanolo, G, 1983) | 0.52 |
" In this study the intramuscular bioavailability of ketoprofen administered as the lysine salt was evaluated in horses (n = 5) treated intravenously and intramuscularly (2." | ( Intramuscular bioavailability of ketoprofen lysine salt in horses. Anfossi, P; Carli, S; Montesissa, C; Villa, R, 1997) | 0.58 |
Dosage Studied
Excerpt | Relevance | Reference |
---|---|---|
" The calculated steady state plasma concentrations of ketoprofen during multiple dosage were much higher after intramuscular (0." | ( Intramuscular bioavailability of ketoprofen lysine salt in horses. Anfossi, P; Carli, S; Montesissa, C; Villa, R, 1997) | 0.58 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (37)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 5 (13.51) | 18.7374 |
1990's | 8 (21.62) | 18.2507 |
2000's | 6 (16.22) | 29.6817 |
2010's | 11 (29.73) | 24.3611 |
2020's | 7 (18.92) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 44.80
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (44.80) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 14 (30.43%) | 5.53% |
Reviews | 2 (4.35%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 30 (65.22%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Clinical Trials (4)
Trial Overview
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
"MISTRAL (Mouthwash In Sore Throat Relief: Antiinflammatory vs. Local Anesthetic Therapy) Efficacy and Tolerability of Ketoprofen Lysine Salt as a Mouthwash in Acute Phlogosis of the Pharyngeal Cavity; Multicentre, Randomized, Single-blind, Parallel-group [NCT02178293] | Phase 4 | 214 participants (Actual) | Interventional | 1998-09-30 | Completed | ||
A Bioequivalence Study of a Test Formulation of Ketoprofen Oral Gel 25 mg Versus a Marketed Reference of Ketoprofen Lysine Salt as Granules for Oral Solution (80 mg Bipartite Sachet, Half Sachet) After Single Dose Administration Under Fed Conditions to He [NCT04678076] | Phase 1 | 36 participants (Actual) | Interventional | 2018-07-23 | Completed | ||
A Multicenter, Double Blind, Randomised, Parallel Study to Assess Efficacy and Tolerability After Single Administration of Ketoprofen Lysine Salt 40 mg Granules vs Placebo in Subjects With Acute Pain Syndrome After Removal of Molar Teeth [NCT03836807] | Phase 3 | 70 participants (Actual) | Interventional | 2018-04-04 | Completed | ||
A Phase I, Double-Blind, PK, Safety, Tolerability Study of KSL + KLS-GABA vs KLS Alone in Healthy Males (Part A) Followed by a Study to Investigate the PD of KLS and KLS + GABA in Healthy Males (Part B) [NCT04802967] | Phase 1 | 140 participants (Actual) | Interventional | 2021-02-08 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |